Personalized frailty-based treatment for older adults with new multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a personalized treatment approach for people aged 65 and older with newly diagnosed multiple myeloma. The goal is to tailor therapy based on each patient's level of frailty, which could help improve outcomes and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older
- You have newly diagnosed multiple myeloma and have not had any prior treatment for it
- You have measurable disease (specific levels of M-protein or light chains in blood or urine)
- Your organs are functioning well enough to handle chemotherapy
- You do not have active serious infections or severe heart or liver problems
- You are willing to sign a consent form and follow the study rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different ways to treat people who are newly diagnosed with multiple myeloma that has a change in chromosome 1 (+1q). The goal is to find the best treatment plan based on each person's risk level.
This trial tests a new combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people who are older or frail and have just been diagnosed with multiple myeloma. It aims to see if this treatment can help control the disease better, especially if certain cancer cells are found in the blood.
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.